Amytrx and Amarex Clinical Research, LLC, an NSF company, announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx's...
Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company"), announced that the first subject has been dosed in the Company's Phase 1a single ascending dose...
Axon Therapies, a private company focused on addressing a root cause of heart failure, announced positive early results from a roll-in cohort for their...
SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, announced dosing of the first human subjects in its phase 1 clinical...
